In the case of TKI treatment for NSCLC patients with ALK fusion, it has been reported that the interaction of the pyrazolopiperidine tail of crizotinib with G1202 at the solvent surface area is important for the appropriate binding of crizotinib to ALK [32]. This evidence concerns the gene ALK and non-small cell lung carcinoma.